Invention Grant
- Patent Title: Formulations of (S)-3-(1-(9H-purin-6-ylamino)ethyl)-8-chloro-2-phenylisoquinolin-1(2H)-one
-
Application No.: US16734135Application Date: 2020-01-03
-
Publication No.: US11312718B2Publication Date: 2022-04-26
- Inventor: Pingda Ren , Michael Martin , Paul Isbester , Benjamin S. Lane , Jason Kropp
- Applicant: Infinity Pharmaceuticals, Inc.
- Applicant Address: US MA Cambridge
- Assignee: Infinity Pharmaceuticals, Inc.
- Current Assignee: Infinity Pharmaceuticals, Inc.
- Current Assignee Address: US MA Cambridge
- Agency: Cooley LLP
- Main IPC: C07D473/34
- IPC: C07D473/34 ; A61K31/52 ; A61P35/00 ; A61P37/00 ; A61P11/06 ; A61P29/00
Abstract:
Polymorphs of chemical compounds that modulate kinase activity, including PI3 kinase activity, and compounds, pharmaceutical compositions, and methods of treatment of diseases and conditions associated with kinase activity, including P13 kinase activity, are described herein. Also provided herein are processes for preparing compounds, polymorphs thereof, and pharmaceutical compositions thereof.
Information query
